2.34
price down icon6.77%   -0.17
after-market After Hours: 2.34
loading

Proqr Therapeutics N V Stock (PRQR) Latest News

pulisher
03:07 AM

ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

03:07 AM
pulisher
Feb 23, 2025

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat

Feb 23, 2025
pulisher
Feb 17, 2025

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) market cap touched US$250m last week, benefiting both individual investors who own 59% as well as institutions - Simply Wall St

Feb 17, 2025
pulisher
Feb 14, 2025

Analyzing ProQR Therapeutics (NASDAQ:PRQR) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World

Feb 14, 2025
pulisher
Feb 13, 2025

Head to Head Contrast: ProQR Therapeutics (NASDAQ:PRQR) versus Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World

Feb 13, 2025
pulisher
Feb 12, 2025

Jones Trading sets ProQR stock Buy rating, $11 price target - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Feb 12, 2025
pulisher
Feb 12, 2025

Jones Trading Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Buy Recommendation - Nasdaq

Feb 12, 2025
pulisher
Feb 11, 2025

Jones Trading sets ProQR stock Buy rating, $11 price target By Investing.com - Investing.com Australia

Feb 11, 2025
pulisher
Feb 11, 2025

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17% - Yahoo Finance

Feb 11, 2025
pulisher
Feb 04, 2025

ProQR Therapeutics (NASDAQ:PRQR) Receives Average Rating of "Buy" from Analysts - MarketBeat

Feb 04, 2025
pulisher
Jan 31, 2025

ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages - Defense World

Jan 31, 2025
pulisher
Jan 27, 2025

Ballentine Partners LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jan 27, 2025
pulisher
Jan 23, 2025

Analysts Offer Predictions for PRQR FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Cantor Fitzgerald Weighs in on PRQR FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 14, 2025

ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

ProQR Therapeutics' SWOT analysis: RNA editing firm's stock poised for growth - Investing.com

Jan 13, 2025
pulisher
Jan 12, 2025

Oppenheimer Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jan 12, 2025
pulisher
Jan 09, 2025

ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Consensus Target Price from Analysts - Defense World

Jan 09, 2025
pulisher
Jan 06, 2025

ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat

Jan 06, 2025
pulisher
Dec 19, 2024

BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Dec 19, 2024
pulisher
Dec 17, 2024

ProQR Therapeutics' SWOT analysis: RNA-editing stock poised for clinical leap - Investing.com

Dec 17, 2024
pulisher
Dec 15, 2024

ProQR Therapeutics’ (PRQR) “Market Outperform” Rating Reiterated at JMP Securities - Defense World

Dec 15, 2024
pulisher
Dec 15, 2024

ProQR Therapeutics’ (PRQR) Buy Rating Reiterated at HC Wainwright - Defense World

Dec 15, 2024
pulisher
Dec 14, 2024

ProQR Therapeutics (NASDAQ:PRQR shareholders incur further losses as stock declines 21% this week, taking five-year losses to 70% - Simply Wall St

Dec 14, 2024
pulisher
Dec 14, 2024

Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding - Simply Wall St

Dec 14, 2024
pulisher
Dec 14, 2024

ProQR Therapeutics (NASDAQ:PRQR) Earns “Buy” Rating from Chardan Capital - Defense World

Dec 14, 2024
pulisher
Dec 13, 2024

Leiden-based biotech company ProQR bags €7.7M - Silicon Canals

Dec 13, 2024
pulisher
Dec 12, 2024

ProQR shares hold price target, buy rating on RNA tech optimism - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

JMP Securities Reiterates Market Outperform Rating for ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

ProQR Therapeutics (NASDAQ:PRQR) Receives "Buy" Rating from Chardan Capital - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

ProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC Wainwright - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

ProQR Therapeutics announces $8.1M in new funding from RSRT - Yahoo Finance

Dec 12, 2024
pulisher
Dec 12, 2024

RNA specialist ProQR Therapeutics NV bags US$8.1m funding - European Biotechnology News

Dec 12, 2024
pulisher
Dec 12, 2024

ProQR secures $9.1M for Rett syndrome trial By Investing.com - Investing.com South Africa

Dec 12, 2024
pulisher
Dec 11, 2024

ProQR secures $9.1M for Rett syndrome trial - Investing.com India

Dec 11, 2024
pulisher
Dec 11, 2024

ProQR Therapeutics Announces $8.1 Million in New Funding - GlobeNewswire

Dec 11, 2024
pulisher
Dec 11, 2024

ProQR Secures $8.1M Funding Boost to Advance Revolutionary Rett Syndrome Treatment - StockTitan

Dec 11, 2024
pulisher
Dec 10, 2024

ProQR Therapeutics' SWOT analysis: RNA editing stock faces pivotal clinical phase - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist - The Manila Times

Dec 10, 2024
pulisher
Dec 10, 2024

ProQR Therapeutics Strengthens RNA Editing Leadership with Key ADAR Expert Appointment - StockTitan

Dec 10, 2024
$74.40
price up icon 0.53%
$22.96
price up icon 2.04%
$33.69
price down icon 0.33%
$357.50
price down icon 0.20%
$110.97
price down icon 5.14%
biotechnology ONC
$259.70
price up icon 0.47%
Cap:     |  Volume (24h):